PT - JOURNAL ARTICLE AU - Epperly, David E. AU - Rinehart, Kristopher R. AU - Caney, David N. TI - COVID-19 Aerosolized Viral Loads, Environment, Ventilation, Masks, Exposure Time, Severity, And Immune Response: A Pragmatic Guide Of Estimates AID - 10.1101/2020.10.03.20206110 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.03.20206110 4099 - http://medrxiv.org/content/early/2020/11/16/2020.10.03.20206110.short 4100 - http://medrxiv.org/content/early/2020/11/16/2020.10.03.20206110.full AB - It can be shown that over 94% of COVID-19 superspreading events occurred in limited ventilation areas suggesting that aerosolized transmission is a strong contributor to COVID-19 infections.This study helps answer the questions “How long may a person safely remain within various environments” and “What exposure levels could result in immunity without becoming ill via asymptomatic graduated inoculation”.Understanding how COVID-19 infection likelihood, symptom severity, and immune response correlate to aerosolized viral load concentration exposure levels and time durations could enable optimized Non-Pharmaceutical Interventions (NPI) that reduce severe case counts and improve at-large epidemiologic responses. The model herein estimates the relationships between aerosolized viral load concentrations present in a given environment containing infected persons, the exposure time duration, ventilation, mask usage, exercise / activity level, and likelihood of infection, severity level, and immune response.This study references peer reviewed and published studies and uses them as data sources. Measured aerosolized viral load concentration data from a hospital environment is used to estimate exposure time durations associated with exposures at multiple viral load levels, within multiple indoor ventilation and outdoor environment scenarios, with the exposed subject respirating at both light activity and heavy exercise liter-per-minute volumes, and without and without wearing surgical masks. Information from ASHRAE Office Ventilation standards and an Outdoor Air Exchange model are a part of the model. This estimated total viral load accumulated within specific exposure time durations in the various environmental scenarios is then interpreted using human challenge viral load escalation data into severity categories including Not Ill, Minor Illness, Clinical Mild Illness, and Possible Severe Illness. Immune response data related to these categories is also provided along with discussion related to asymptomatic infection, graduated inoculation, and immunity.When appropriately interpreted for individualized applications, the estimates herein could contribute to guidance for those at low-risk for a severe case that have no obvious COVID-19 co-morbidities, with the understanding that those at higher risk should seek to avoid all exposure risk. The estimates herein may help efforts to strike a balance in developing holistic epidemiologic interventions that consider the effects of these interventions on economic, civic, social, and mental health, which have pathologies within their own realms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors performed all work on this study without compensation as an act of good will and statesmanship and have no beneficial affiliations with any institutions related to the work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a meta-study that does not require IRB approval. We don't know if it requires EQUATOR Network submission and need assistance in this area.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe manuscript contains all relevant data and references.